Friday, October 23, 2020 9:10:06 AM
8:17 am ET October 23, 2020 (Dow Jones) Print
By Chris Wack
Ultragenyx Pharmaceutical Inc. and Solid Biosciences Inc. said Friday they entered into a strategic collaboration and license agreement to focus on the development and commercialization of new gene therapies for Duchenne.
The companies said they will collaborate to develop products that combine Solid's differentiated microdystrophin construct, Ultragenyx's HeLa producer cell line manufacturing platform, and AAV8 variants.
Under the terms of the collaboration, Solid granted Ultragenyx an exclusive license for any pharmaceutical product that expresses Solid's proprietary microdystrophin construct from AAV8 and variants thereof in clade E for use in the treatment of Duchenne and other diseases resulting from lack of functional dystrophin, including Becker muscular dystrophy.
Ultragenyx has made a $40 million investment in Solid and has agreed to pay up to $255 million in cumulative milestone payments per product upon achievement of specified milestone events, and tiered royalties on worldwide net sales at low double digit to mid-teens percentages. Upon achievement of proof-of-concept, Solid has the right to opt-in to co-fund collaboration programs in return for participation in a profit share or increased royalty payments.
Solid Biosciences shares rose 30% to $4.50 in premarket trading. Ultragenyx shares were up 2% to $93.90 premarket.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 23, 2020 08:17 ET (12:17 GMT)
New York Yankees and Duke Basketball
Recent SLDB News
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/02/2024 08:15:00 PM
- Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference • GlobeNewswire Inc. • 09/23/2024 12:00:00 PM
- Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/12/2024 12:00:00 PM
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/04/2024 08:05:00 PM
- Solid Biosciences to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 09/04/2024 12:00:00 PM
- Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/13/2024 08:08:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:01:21 PM
- Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/02/2024 10:37:28 PM
- Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/01/2024 08:19:02 PM
- Solid Biosciences Joins the Russell 3000® Index • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:13:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:10:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:06:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:05:32 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/12/2024 12:43:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:22:02 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/11/2024 08:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 06:15:59 PM
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/04/2024 08:00:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:32 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/15/2024 12:26:42 PM
- Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/15/2024 11:52:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 11:30:36 AM
- Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM